XM does not provide services to residents of the United States of America.

Global Payments divests medical software unit for $1.1 bln to sharpen core focus



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-Global Payments divests medical software unit for $1.1 bln to sharpen core focus</title></head><body>

Adds deal value in headline and paragraph 1, analyst comment in paragraphs 4-5, context throughout

By Niket Nishant

Oct 30 (Reuters) -Global Payments GPN.N will sell its medical software business, AdvancedMD, to investment firm Francisco Partners for $1.13 billion, they said on Wednesday, as the financial technology firm looks to slim down and focus on core operations.

The payments technology provider has pledged to streamline operations and divest assets not central to its businesses, with plans to allocate some of the proceeds to enhance shareholder returns.

Global Payments also unveiled a $600 million accelerated stock buyback plan on Wednesday.

"We didn't consider AdvancedMD a priority asset for Global Payments to sell as we thought stickiness and payment monetization made it worth keeping," said J.P.Morgan analyst Tien-tsin Huang.

But the sale will help "simplify the business around core payment processing," Huang said.

Founded in 1999, AdvancedMD provides payments and other software services to independent physicians and small-to-medium sized healthcare facilities in the United States.

Global Payments had acquired AdvancedMD in a $700 million deal in 2018. Francisco was also an investor in the company years ago.

The investment firm has bought healthcare analytics and medical services units from CVS Health CVS.N, IBM IBM.N and Qualcomm QCOM.O over the past few years.

The deal for AdvancedMD is expected to close in the fourth quarter. Moelis & Company was the financial adviser to Francisco, while Bank of America advised Global Payments.

Separately in the day, Global Payments reported a near 13% drop in its third-quarter profit due to higher costs.

Shares of the company were down nearly 3% before the bell.



Reporting by Niket Nishant in Bengaluru; Editing by Shilpi Majumdar

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.